A wonderful business — priced for growth it hasn't delivered.

A great company, but no margin of safety at this price. Worth watching, not worth buying here.

Price $120.97 taken 2026-11-15 · market cap about $24B
Fair value $69 range $55 to $90 · from the FY25 annual report
Margin of safety −43%, above fair value no margin of safety · the price sits above fair value

The five checks

4 good · 1 warning

  • Warning
    Overvalued
    Fair value ~$69 vs $121 — trading 43% above what the math supports.
  • Good
    Price is in line with its record
    Priced for ~14%/yr, roughly what it has delivered (14.9%/yr).
  • Good
    Revenue still growing
    Up 21.2% last year — demand isn't the problem.
  • Good
    Cash flow compounding
    Free cash flow up ~14.9%/yr — the engine is growing.
  • Good
    Fortress balance sheet
    Net cash positive (+$3B) — little solvency risk.

Price against fair value

What today's price assumes

Hold the price fixed and work backwards: how fast would free cash flow have to grow for $121 to make sense?

The price needs ~14% a year
Incyte has delivered 14.9% a year over the last three years

Price is in line with its record.

Where this number comes from →

How fair value is calculated

No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.

  1. Free cash flow, typical yearThe five-year norm, from the annual reports$0.57B
  2. Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$4.67B
  3. Everything after year tenGrowing 2.5% a year, counted the same way+ $6.18B
  4. The business, in today's money$10.85B
  5. Add net cashCash and securities less borrowings and finance leases+ $3.06B
  6. Divide by the shares on file÷ 0.2007B

Fair value per share$69

If our assumptions are wrong

Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $55 to $90 range comes from.

3% growth5% growth7% growth
8% discount$70$80$90
9% discount$62$69$78
10% discount$55$62$69

The blue cell is the published method. Every cell sits below today’s price.

Free cash flow, ten years

$ billions · Form 10-K

$0.2B FY16 −$0.2B FY17 $0.3B FY18 $0.6B FY19 −$0.3B FY20 $0.6B FY21 $0.9B FY22 $0.5B FY23 $0.3B FY24 $1.4B FY25
  1. FY25 $1.4B
  2. FY24 $0.3B
  3. FY23 $0.5B
  4. FY22 $0.9B
  5. FY21 $0.6B
  6. FY20 −$0.3B
  7. FY19 $0.6B
  8. FY18 $0.3B
  9. FY17 −$0.2B
  10. FY16 $0.2B

What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.

How this was built. Every figure is computed from Incyte Corporation's SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Fair value is based on typical free cash flow over the last five years ($0.6B), not the latest year ($1.4B), which sat 137% above the company's own norm. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $120.97 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.

Read Incyte another way

TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →